Abstracts Archive - Page 1849 of 2607 - ACR Meeting Abstracts

Abstract Number: 2929 • 2015 ACR/ARHP Annual Meeting
Diet and Glucocorticoid Treatment in Patients with SLE
Cecilia Lourdudoss¹, Johan Frostegård² and Ronald F. van Vollenhoven³, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Relatively little is known about the link between diet and treatment results in SLE. Glucocorticoids (GC) are used to control active SLE but minimized…
Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 2931 • 2015 ACR/ARHP Annual Meeting
Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Chi Chiu Mok¹, Sau Mei Tse¹, Ling Yin Ho² and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate whether pregnancy is a risk factor for the onset of SLE in women of the reproductive age.Methods: Female patients who had first…
Abstract Number: 2932 • 2015 ACR/ARHP Annual Meeting
A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide
Nídia Oliveira¹, Mónica Ibañez², Natalia Ciang³ and David A. Isenberg⁴, ¹Internal Medicine Department, Hospital Pedro Hispano, Matosinhos, Portugal, London, United Kingdom, ²Rheumatology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain, London, United Kingdom, ³Rheumatology Department, Queen Eliazbeth Hospital, Hong Kong, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity. Many patients with refractory disease can not tolerate conventional immunosuppressive therapy. The aims of this…
Abstract Number: 2933 • 2015 ACR/ARHP Annual Meeting
Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Teja Kapoor¹, Jianhua Li², Sameer Malhotra³, Joan Bathon⁴ and Anca Askanase⁵, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Weill Cornell Medical Center, New York, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : The risk of Pneumocystis carinii pneumonia (PCP) in Systemic Lupus Erythematosus (SLE) is not well-established. Accordingly, this study aims to establish the prevalence…
Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting
Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Helena Tydén¹, Christian Lood², Birgitta Gullstrand³, Andreas Jönsen⁴ and Anders A. Bengtsson⁵, ¹Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Lund University Hospital, Lund, Sweden, ⁵Rheumatology, Inst of Clinical sciences, Lund, Sweden
Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Roa'a Al Johani¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…
Abstract Number: 2936 • 2015 ACR/ARHP Annual Meeting
Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Murray Urowitz^1,2, Dafna Gladman¹, Nicole Anderson³, Jiandong Su¹ and Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The evolution on an annual basis of disease activity and damage and the annual accrual of ACR criteria and key autoantibodies in patients with…
Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
J. Madison Hyer¹, Bethany Wolf¹, Jim Oates², Gary S. Gilkeson³ and Diane L. Kamen², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Department of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 2939 • 2015 ACR/ARHP Annual Meeting
The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
Mary Anne Dooley¹, Brad H. Rovin², Jai Radhakrishnan³, Ellen M. Ginzler⁴, Tammy Forrester⁵ and Pamela Anderson⁶, ¹Medicine-Rheumatology-Immun, U of NC at Chapel Hill, Chapel Hill, NC, ²Ohio State University Medical Center, Columbus, OH, ³Presbyterian Hospital, Columbia University, New York, NY, ⁴Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ⁵Eli Lilly & Company, Indianapolis, IN, ⁶Eli Lilly & Co, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane and soluble B-cell activating factor. Two 52-week, randomized, double-blinded, placebo-controlled Phase 3 trials, designated BCDS and…
Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Khawla Al-Ghanim¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Mohammed Attar⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, TWH, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…
Abstract Number: 2941 • 2015 ACR/ARHP Annual Meeting
Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Manish Rathi¹, Ajay Jaryal², Ajay Goyal², Aman Sharma³, Pramod Gupta⁴ and Krishan Gupta², ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Biostatistics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Management of SLE and lupus nephritis is challenging as it is always a trade off between remission, prevention of relapse and long term adverse…
Abstract Number: 2942 • 2015 ACR/ARHP Annual Meeting
Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus
Aline Tamires Lapa¹, Nailu A. Sinicato², Mariana Postal¹, Fernando Cendes³, Roberto Marini Sr.⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁵Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil
Background/Purpose: The CNS involvement in cSLE has been described to occur from 25-90% in childhood-onset systemic lupus erythematosus (cSLE). The aim of the study was…
Abstract Number: 2943 • 2015 ACR/ARHP Annual Meeting
Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program
Peter M. Izmirly¹, Isabella Wan², Sara Sahl¹, Jill P. Buyon³, H. Michael Belmont⁴, Jane E. Salmon^5,6, Joan M. Bathon⁷, Anca Askanase⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen M. Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles G. Helmick¹⁴ and Hilary Parton¹⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Dept of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁸Columbia University College of Physicians & Surgeons, New York, NY, ⁹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ¹³School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁴Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ¹⁵Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: Given widely varying estimates of the incidence and prevalence of Systemic Lupus Erythematous (SLE) in the US and the absence of data for certain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].